Post Doctoral Training Fellow
Health and Medical,Medicine and Dentistry,Anatomy, Physiology and Pathology,Biological Sciences,Biology,Genetics,Molecular Biology and Biophysics
Short info about job
Company: Institute of Cancer Research
Department: Radiotherapy and Imaging
Salary: £29,960 to £42,820 per annum. Starting salary will be based on previous postdoctoral experience
Hours: Full Time
Contract type: Fixed-Term/Contract
Type / Role: Academic or Research
Phone: +44-1423 7570098
Fax: +44-1341 7168823
E-mail: N\A
Site: N\A
Detail information about job Post Doctoral Training Fellow. Terms and conditions vacancy
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.
The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
Combining Immuno-oncology Agents with Radiotherapy / Chemoradiotherapy
We are looking for a highly motivated and talented scientist to join the Targeted Therapy Team lead by Professor Kevin Harrington at the Institute of Cancer Research in London.
The primary goal of this research program is to expand on research in our lab on radiation and DNA damage response inhibitors. The successful candidate will be involved in exploring the immunological consequences of radiation and DNA damage response inhibition using established immunocompetent in vivo models. This research project aims to understand the potential efficacy of combining existing and/or emerging immuno-oncology agents with radiotherapy and DNA repair inhibitors.
We are looking for candidates that have significant knowledge in any area of immune cell biology. Hands-on experience in flow cytometry analysis of immune cell phenotypes is absolutely critical. Prior working experience with in vivo models is also essential. Additional knowledge of immunohistochemistry, automated image analysis, Nanostring, RNAseq or TCRseq would be desirable but is not essential.
Applicants will hold a PhD in cell and molecular biology, immunology or a similar discipline. Within the laboratory and ICR you will get guidance and knowledge from cancer biology and translational studies experts and you will be included in programs to develop your career. While previous immunology experience is essential, previous knowledge in cancer or radiation biology while desirable is not a requirement.
Applicants must have good laboratory and analytical skills with experience in working in a collaborative environment. Candidates should be capable of working independently, be ambitious and driven to achieve goals.
You are expected to publish in leading journals and present your data in internal and external meetings. This is an ideal opportunity for a committed and enthusiastic scientist to join a dynamic research team with excellent collaborators and facilities at a highly recognised institute.
This appointment is offered on a fixed term contract of 3 year in the first instance with a full salary scale within the range of £29,960 p.a. to £42,820 p.a. based on previous postdoctoral experience.
To apply please submit your CV and covering letter (addressing with specific examples where you meet the person specification and incl. the names and addresses of two referees) by clicking on the apply button below.
We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff.